Search
Arbutin
go.drugbank.com/drugs/DB11217ApprovedIt has also been used as an anti-infective for the urinary system as well as a diuretic [F43]. … Most commonly, it is an active ingredient in skincare and cosmetic products as a skin-lightening agent for the prevention of melanin formation in various skin conditions that involve cutaneous hyperpigmentation
gamma-Hydroxybutyric acid
go.drugbank.com/drugs/DB01440ApprovedIllicitInvestigationalIt is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. … Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … [A225933] Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit EBOV outbreak 11 years after infection, which displays strong glycan-independent binding to a
Equus caballus dander
go.drugbank.com/drugs/DB11021ApprovedEquus caballus dander is the dander of Equus caballus. Equus caballus dander is used in allergenic testing.
Mixtures: Animal Allergens, AP Horse Hair and Dander, Animal Allergens, AP Horse Hair and DanderTemafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnTemafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. … It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three
Aminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnAminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. … The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Synonyms: AMDAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Products: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML